Assets Sale, Donations, Clinical Research Data, IPO Filing, and Earnings Release Schedules - Analyst Notes on HSBC, BP, GSK,

   Assets Sale, Donations, Clinical Research Data, IPO Filing, and Earnings       Release Schedules - Analyst Notes on HSBC, BP, GSK, Shell and BAT  Editor Note: For more information about this release, please scroll to bottom.    PR Newswire    LONDON, June 27, 2014  LONDON, June 27, 2014 /PRNewswire/ --  Today, Earnings Review released its analysts' notes regarding HSBC Holdings Plc (LON: HSBA), BP Plc (LON: BP), GlaxoSmithKline Plc (LON: GSK), Royal Dutch Shell Plc (LON: RDSA) and British American Tobacco Plc (LON: BATS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: . HSBC Holdings Plc Analyst Notes On June 24, 2014, HSBC Holdings Plc (HSBC) announced that its indirect wholly-owned subsidiary HSBC Private Bank (Suisse) SA has agreed to sell a portfolio of its private banking assets in Switzerland to LGT Bank (Switzerland) Ltd, a wholly-owned subsidiary of the LGT Group Foundation. HSBC informed that the portfolio had $12.5 billion in assets under management as at December 31, 2013. HSBC expects the transaction to be completed in Q4 2014. The full analyst notes on HSBC are available to download free of charge at: BP Plc Analyst Notes On June 24, 2014, BP Plc (BP) announced that it has made a $2.5 million donation to the 2015 Chicago Architecture Biennial and will serve as the major sponsor of the three-month long exhibition. Commenting on the development, John Mingé, BP America Chairman and President, said, "BP has a long history of supporting programs, events and institutions that make Chicago great, and we're proud to sponsor this celebration of the city's significant contribution to world architecture." The first-ever Chicago Architecture Biennial, to be held from October 1, 2015 through January 3, 2016, will include a number of exhibitions and educational programs featuring many of the world's leading architects. The full analyst notes on BP are available to download free of charge at: GlaxoSmit hKline Plc Analyst Notes On June 14, 2014, GlaxoSmithKline Plc (GSK) presented new data from secondary analyses of four randomised phase III studies at the 74th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco. The new data showed that patients enrolled in the studies who remained on Tanzeum/Eperzan (albiglutide), a once-weekly glucagon-like peptide (GLP-1) receptor agonist, continued to show blood glucose lowering at three years, consistent with results at the one year or 52 week primary endpoint. Vlad Hogenhuis, Senior Vice-President and Head, Cardiovascular, Metabolic and Neurosciences Franchise, GSK, said, "While many phase III trials in type 2 diabetes are typically six months in duration, we set out to assess weekly-administered albiglutide for up to three years. We are proud to be able to present these data which further characterize the efficacy and safety profile of albiglutide." The full analyst notes on GSK are available to download free of charge at: Royal Dutch Shell Plc Analyst Notes On June 18, 2014, Royal Dutch Shell Plc (Shell) announced that its wholly-owned subsidiary Shell Midstream Partners, L.P. has filed for an Initial Public Offering (IPO) with the U.S. Securities and Exchange Commission (SEC). According to a Reuters report dated June 18, 2014, the proposed IPO seeks to raise up to $750 million and the offer proceeds will be used to acquire stakes in Shell's other pipelines. Shell Midstream Partners intends to apply to list the common units on the New York Stock Exchange under the ticker symbol "SHLX". According to the Company, the offering is expected to occur in the second half of this year. Shell Midstream Partners was formed as a vehicle to own, operate, develop and acquire pipelines and other midstream assets. The full analyst notes on Shell are available to download free of charge at: British American Tobacco Plc Analyst Notes As per the Financial Calendar available at British American Tobacco Plc's (BAT) official website, the Company will publish its Half-yearly Report on July 30, 2014. In an announcement dated April 30, 2014, the Company had informed that the half-yearly report will also include announcement of declaration of interim dividend. In Q1 2014, the Company had reported a decline of 1.2% YoY in cigarette volumes, as growth in markets including Bangladesh, Pakistan, Indonesia, Japan and the GCC was offset by lower volumes in Russia and Poland. Group revenue for Q1 2014 grew by 2% at constant rates of exchange, indicating towards lower volume and the timing of price increases, in comparison to Q1 2013. The full analyst notes on BAT are available to download free of charge at: =============== EDITOR'S NOTES: =============== 1. This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] . 5. For any urgent concerns or inquiries, please contact us at compliance [at] . 6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Earnings Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Earnings Review in this article or report according to the procedures outlined by Earnings Review. Earnings Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Earnings Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Earnings Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Earnings Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Earnings Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Earnings Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.  Contact: CONTACT PERSON: Adam Redford, CONTACT PHONE: +1-852-8191-3972  
Press spacebar to pause and continue. Press esc to stop.